Identifying tumor biomarkers in patients with Neurofibromatosis Type 1
Developing Novel Biomarkers of Plexiform Neurofibroma Tumor Burden
Ann & Robert H Lurie Children's Hospital of Chicago · NCT05238909
This study is trying to find specific markers in the blood of people with Neurofibromatosis Type 1 to better understand their tumors and improve how they are monitored and treated.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Sex | All |
| Sponsor | Ann & Robert H Lurie Children's Hospital of Chicago (other) |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT05238909 on ClinicalTrials.gov |
What this trial studies
This study aims to identify tumor biomarkers in individuals diagnosed with Neurofibromatosis Type 1 (NF1), a condition that increases the risk of developing plexiform neurofibromas. The research utilizes blood plasma samples from NF1 patients and employs advanced techniques such as whole-body MRI and mass spectrometry to analyze biomarker profiles. By establishing a pipeline for identifying candidate biomarkers, the study seeks to improve the understanding of tumor burden in NF1 patients and potentially enhance monitoring and treatment strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with a confirmed diagnosis of Neurofibromatosis Type 1.
Not a fit: Patients who do not meet the NF1 diagnostic criteria or have mosaic NF1 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved methods for early detection and monitoring of tumors in patients with Neurofibromatosis Type 1.
How similar studies have performed: While the approach of identifying biomarkers in NF1 is innovative, similar studies in other conditions have shown promise in biomarker discovery.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Individuals with known diagnosis of neurofibromatosis type 1 (NF1) Exclusion Criteria: 1. Patient does not meet NF1 diagnostic criteria 2. Mosaic NF1 individuals 3. Pregnant at Screening 4. Patients who do not have the ability/capacity to undergo the informed consent process OR whose parent/legal guardian is unable to undergo the informed consent process.
Where this trial is running
Chicago, Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States (RECRUITING)
Study contacts
- Principal investigator: Carlos Prada, MD — Ann & Robert H Lurie Children's Hospital of Chicago
- Study coordinator: Carolyn Raski, MS
- Email: craski@luriechildrens.org
- Phone: 312-227-4391
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neurofibromatosis 1, NF1, Neurofibromatosis Type 1, Plexiform neurofibromas, neurofibromatosis type 1, neurofibromas